Sai’s SAB members each bring a unique and important expertise or perspective to ensure that the company builds and maintains quality scientific teams and processes.   In addition, the SAB provides strategic guidance in developing and expanding the services provided by Sai to its clients.

Thomas Baillie, Ph.D.
Anthony G.M. Barrett, Ph.D.
James Bristol Ph.D.
Tamar Howson, MBA, M.S.
John Knight, Ph.D.
Frank W. Marcoux, Ph.D.
Kazumi Shiosaki, Ph.D.
Elizabeth Stoner, MD.
Srivari Chandrasekhar, Ph.D

Thomas Baillie, Ph.D.

Thomas Baillie was educated at the University of Glasgow, where he earned B.Sc. (Honors) and Ph.D. degrees in Chemistry in 1970 and 1973, respectively. He also holds an M.Sc. degree in Biochemistry from the University of London (1978) and was awarded the degree of D.Sc. in Chemistry from the University of Glasgow in 1992. Following postdoctoral research at the Karolinska Institute in Stockholm, Sweden (1973-75), Dr. Baillie held successive faculty positions at the University of London (1975-78), University of California San Francisco (1978-81), and University of Washington (1981-94). He then joined Merck Research Laboratories in West Point, PA, where he was Global Vice President of Drug Metabolism & Pharmacokinetics until 2008, Thomas A. Baillie currently is Dean of the School of Pharmacy at the University of Washington in Seattle, WA. Dr. Baillie’s research interests center on the application of mass spectrometry and allied techniques to mechanistic studies on the metabolism of foreign compounds, with particular emphasis on the generation of chemically-reactive, potentially toxic products of biotransformation. He has co-authored some 200 peer-reviewed publications, serves on the advisory boards of a number of journals and academic research centers, and acts as a consultant to several companies in the pharmaceutical and biotechnology industries. He was awarded a Fogarty Senior International Fellowship from the NIH in 1988, was the recipient of the James R. Gillette Award from the American Society for Pharmacology & Experimental Therapeutics (2001), and received the Lifetime Achievement Award from the International Isotope Society (2009). ^TOP

Anthony G.M. Barrett, Ph.D.

Anthony G.M. Barrett, Ph.D., FRS FMedSci Anthony Barrett obtained his B.Sc. degree with 1st class honors (1973) and his Ph.D. (1975) with Professor Sir Derek H.R. Barton (Nobel Laureate) at Imperial College. He was appointed lecturer in organic chemistry (1975) at Imperial College and senior lecturer (1982). In 1983, he was appointed full professor of Chemistry at Northwestern University in Evanston, Illinois, and in 1990 moved to Colorado State University. After ten years research in the USA, he returned to Imperial College as Glaxo Professor of Organic Chemistry, Director of the Wolfson Centre for Organic Chemistry in Medical Science and Head of the Organic Section. He was appointed the Sir Derek Barton Professor of Synthetic Chemistry in 1999. He has co-authored over 360 publications and is an inventor on over 20 patents on natural product, heterocyclic, organometallic and porphyrazine chemistry, catalysis and parallel synthesis. He has received numerous awards for his contributions to research from the Royal Society of Chemistry, the American Chemical Society, the Royal Society, the Camille and Henry Dreyfus Foundation, the Japan Society for the Promotion of Science, Glaxo Wellcome and the Specialized Organic Sector Association. He was elected a Fellow of the Royal Society (1999) and the Academy of Medical Sciences (2003). He is the co-Founder and Director of Science for Argenta Discovery and iThemba Pharmaceuticals and is a consultant to major international pharmaceutical and chemical companies globally. ^TOP

James Bristol Ph.D.

James Bristol received a B.S. in chemistry from Bates College in 1968 and a Ph.D. in organic chemistry from the University of New Hampshire in 1972. He conducted postdoctoral research at the University of Michigan (N.I.H. Postdoctoral Fellow) and at The Squibb Institute for Medical Research. From 1975 to 2007 he held positions of increasing responsibility in medicinal chemistry and drug discovery at Schering-Plough, Park-Davis, and Pfizer where his final position was Senior Vice President, Worldwide Discovery Research. Since retiring in 2007 he has been an advisor to several biopharmaceutical companies and venture capital firms. He is the chairman of the Strategic and Scientific Advisory Board for Sai Advantium Pharma, Ltd. Professional activities have included officer positions in the ACS Division of Medicinal Chemistry, member of the Board of Trustees of the Gordon Research Conferences, Adjunct Professor of Medicinal Chemistry at the University of Michigan, and Editor in Chief of Annual Reports in Medicinal Chemistry. His research interests have included published work in drug discovery programs related to the treatment of gastrointestinal diseases, CNS diseases, and cardiovascular diseases, with a focus on mechanistic biochemistry, which have been recorded in over 100 publications, abstracts, and patents. ^TOP

Tamar Howson, MBA, M.S.

Tamar Howson holds a MBA from Columbia University, an M.S. from City College of New York, and a B.S. in Chemical Engineering from the Technion, Israel. She joined a transaction advisory firm, JSB-Partners in January 2009. Prior to JSB, she has been a senior corporate and business development executive at several large pharmaceutical companies as well as Lexicon Pharmaceuticals, a biotech company. Between 2001 and 2007 she was the Senior Vice President, Corporate and Business Development at Bristol Myers-Squibb overseeing M&A, licensing, and research across all business sectors. In 2000 and 2001 she was a business development and strategy consultant to several biotechnology companies, served as a Director for Ariad, NPS, SkyePharma and Targacept, a Special Limited partner at Care Capital and several advisory boards. Between 1991 and 2000, she was the Vice President and then Senior Vice President and Director of Worldwide Business and Corporate Development, for SmithKline Beecham. Between 1998 and 2000 she also managed SmithKline Beecham’s $100MM venture capital fund, SR One. Before joining SmithKline, she was a vice president of venture investments at Johnston Associates, a venture capital firm. Prior to that, she was Director of Worldwide Business Development and Licensing for Squibb Corporation. ^TOP

John Knight, Ph.D.

John Knight received a first class honors degree in chemistry and a Ph.D. in synthetic methodology at the University of Southampton, UK. He then worked as a NATO Postdoctoral Fellow with Professor Gilbert Stork at Columbia University, following which he joined the process research and development department at Glaxo. In 1994 he joined Oxford Asymmetry where he developed the Process Research and Development effort and also participated in design, building and commissioning two pilot plants. Following commissioning first plant, he worked as its Production Manager for 3 years. He then was appointed to the position of Vice President, Process Research and Development, where he wrote the majority of the development proposals for clients, assisted in its expansion, established a team to perform polymorph and salt screening studies and established and maintained high standards of development expertise across the department. In this capacity he has managed the chemical development and transfer of more than 30 NCE’s into the plant for clients and been involved in process validations. He has considerable experience in fast tracking projects to the plant through highly focused optimization and project management. He joined Scientific Update in January 2008 as Scientific Director. ^TOP

Frank W. Marcoux, Ph.D.

Frank Marcoux holds a B.S. in Zoology and Chemistry from the University of Massachusetts in 1974 and Ph.D. in Physiology and Biophysics from the University of Alabama in 1979. He has held research positions at Harvard Medical School/Massachusetts General Hospital, University of Alabama, Birmingham, Medical Center, and at the University of Vermont College of Medicine. He joined Parke-Davis in 1983 , where he led drug discovery activities initially in the neurosciences area and then all of biology. In particular, he has focused on drug discovery programs in the neurological and neurodegenerative diseases fields, and specialized in stroke research. In 2000 he joined Pfizer where he held various positions including Vice President, Biology Discipline, Worldwide Discovery Research where his responsibilities included setting a biology discipline strategy and oversight leadership for biology discipline councils and centers of excellence. He was then appointed Vice President, Clinical, Quantitative and Innovative Medicine in Worldwide Clinical Development, where his clinical and translational medicine responsibilities included setting a strategy for biomarkers in translating late stage discovery programs to clinical proof of concepts and participation on the clinical development leadership team. He is President, Discovery Translation, LLC, an independent consulting firm he started upon retirement from Pfizer in 2008. His consulting focus is on high confidence translation of drug discovery programs to early clinical proof of concept and is aimed at biotech, pharmaceutical and academic medical center clients. He has been a member of several professional societies, and was a special reviewer and study section member for the American Heart Association and NIH-NINDS. He has served on editorial boards and as reviewer for numerous journals and has co-edited a book in the field of experimental neurology. ^TOP

Kazumi Shiosaki, Ph.D.

Kazumi Shiosaki received a B.S. in Chemistry from Whitman College and a Ph.D. in Chemistry from the University of California, Berkeley. She began her career in the pharmaceutical industry at Abbott Laboratories where she worked on drug discovery programs in a number of therapeutic areas including Neuroscience, Cardiovascular, and Infectious Disease. She then joined Millennium Pharmaceuticals where she was Senior Vice President, Scientific Development and Drug Discovery. While at Millennium, she was instrumental in helping to transition Millennium into a drug discovery organization and was involved in helping to secure, as well as to manage, a number of the large corporate alliances in genomic targets (Bayer), metabolic diseases (Abbott) and in inflammation (Aventis). Currently she is a Managing Director at MPM Capital where she has worked closely with a number of the firm's portfolio companies to advance their small molecule discovery and development programs, including Hypnion, Aryx, and Oxagen. She was the founding CEO of Primera Diagnostics, a molecular diagnostics company focused on infectious disease and oncology products. She is currently the CEO of Epizyme, a company she helped to found that is focused on discovering and developing small molecules that modulate newly characterized epigenetic enzymes involved in cancer and other diseases. ^TOP

Elizabeth Stoner, MD.

Elizabeth Stoner received a B.S. in Chemistry from Ottawa University, KS, an M.S. in Chemistry from the State University of New York at Stony Brook, and an M.D. from Albert Einstein College of Medicine. Following her medical degree, she was appointed Assistant Professor of Pediatrics at Cornell University Medical College, following which she joined Merck, where she led the entire Proscar clinical development program from inception, establishing Merck as a leader in the field of prostate disease. As Endocrine Therapeutic Head, her responsibilities included all steroid and lipid metabolism, as well as the growth hormone secretagogue clinical research programs. At the time of her retirement from Merck, she was Senior Vice President of Global Clinical Development Operations with responsibility for the company's clinical development activities in more than 40 countries. She also oversaw the clinical development activities of Merck's Japanese partner Banyu, led the clinical development for the Merck/Schering-Plough Joint Venture for Zetia/Vytorin, and played a critical leadership role in Merck's efforts to transform its worldwide clinical development operations. In 2007 she joined MPM Capital, where she is a Managing Director. ^TOP

Srivari Chandrasekhar, Ph.D

Srivari Chandrasekhar obtained all his primary education in Hyderabad, India. After obtaining a Ph.D. under the supervision of Dr. A. V. Ramarao at the Indian Institute of Chemical Technology, Hyderabad, he moved to the University of Texas Southwestern Medical School for post-doctoral research with Professor J. R. Falck and then to the University of Goettingen, Germany as Alexander von Humboldt Fellow in the group of Professor L. F. Tietze. His research interests include the synthesis of marine natural products, peptides and peptidomimetics, combinatorial chemistry and new solvent media for organic synthesis. He is a recipient of a Young Scientist award of the Indian National Science Academy, B M Birla Science Prize and National Academy of Sciences-Reliance Industries Platinum Jubilee Award. He has over 190 publications, 2 patents, and guided 20 students for their Ph.D. degrees. Presently he is a deputy director at the Indian Institute of Chemical Technology where he supervises a group of 30 researchers. ^TOP